Newsfeeds - Spark Newswire

5 minute read

Akerna Shares Dip 53%, Here’s 78 Biggest Movers From Yesterday

Today, 3:44 AM

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.

ADSE

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 3:44 AM

Gainers

ACRX

1 minute read

William Blair Downgrades Aileron Therapeutics to Market Perform

By Benzinga Newsdesk

Today, 3:44 AM

William Blair analyst Matt Phipps downgrades Aileron Therapeutics (NASDAQ:ALRN) from Outperform to Market Perform.

ALRN

4 minute read

Aileron Therapeutics Announced Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

By Charles Gross

Today, 3:44 AM

Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients' lives, today announced interim data from its Phase 1b chemoprotection trial of patients with advanced p53-mutated NSCLC undergoing treatment with first-line carbopla

ALRN

1 minute read

Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights

Today, 3:44 AM

Gainers bluebird bio (NASDAQ:BLUE) shares rose 53.4% to $6.12 during Friday's after-market session. Trading volume for this security closed at 5.0 million, accounting for 206.3% of its average full-day volume over the last 100 days. The company's market cap stands at $437.2 million.

ABVC

1 minute read

Aileron Treats First Patient With ALRN-6924 In Breast Cancer Setting

By Ragothaman Srinivasan

Today, 3:44 AM

Aileron Therapeutics (NASDAQ: ALRN) enrolled the first patients in its Phase 1b clinical trial evaluating ALRN-6924 for bone marrow in patients patients with p53-mutated breast cancer who are being treated with doxorubicin plus cyclophosphamide and docetaxel (AC+D).

ALRN

4 minute read

50 Biggest Movers From Yesterday

By Lisa Levin

Today, 3:44 AM

Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) shares gained 81.3% to close at $2.32 on Monday. Last week, AMC Entertainment Holdings purchased a major stake in Hycroft Mining Holding.

ALRN

1 minute read

Aileron Therapeutics Q4 EPS $(0.08) Up From $(0.12) YoY

By Benzinga Newsdesk

Today, 3:44 AM

Aileron Therapeutics (NASDAQ:ALRN) reported quarterly losses of $(0.08) per share. This is a 33.33 percent increase over losses of $(0.12) per share from the same period last year.

ALRN

5 minute read

64 Biggest Movers From Friday

By Lisa Levin

Today, 3:44 AM

Gainers Clever Leaves Holdings Inc. (NASDAQ: CLVR) shares surged 143% to settle at $3.84 on Friday after the company reported better-than-expected Q4 sales results and reaffirmed FY22 guidance.

AGFY

2 minute read

Movers

12 Health Care Stocks Moving In Friday’s Intraday Session

By Benzinga Insights

Today, 3:44 AM

ALRN